1. The Scandinavian Sarcoma Group 25 Years´Jubilee Meeting St
The Scandinavian Sarcoma Group 25 Years´Jubilee Meeting St. Petersburg, May 4-7, 2004

3. Sarcoma tumor board Patient Treatment plan Orthopaedic surgeon
Plastic
Head & Neck
Neuro
Thorax
Abdominal
Cytologist
Pathologist
Cytogenetics
X-ray diagnostician
Patient
Oncologist
Treatment plan
Surgery Radiotherapy: Preoperative Chemotherapy: Neoadjuvant
Intraoperative Adjuvant
Postoperative Intra-arterial
Sequential Tumour necrosis factor a
Brachytherapy isolated limb perfusion
Hyperthermia
Follow-up during and after treatment
Centralized registration

4. SSG Register Chairman H. Bauer Stockholm
Coordinators K. Sundby Hall Oslo Ö. Berlin Gothenburg
P. Gustafson Lund
C. Trovik Bergen
R. Huuhtanen Helsinki

6. Theses planed Leiomyosarcoma C. Svarvar, Helsinki
Liposarcoma K. Engström, Gothenburg
Chondrosarcoma B. Widhe, Stockholm
Osteosarcoma C. Müller, Oslo
Quality of life L. H. Aksnes, Oslo
Skeletal metastases B. H. Hansen, Århus
Radiation therapy and local recurrence in STS N. L. Jebsen, Bergen

7. Soft Tissue Sarcoma SSG I Adjuvant chemotherapy in STS 1981 – 86
SSG V Treatment program for STS –
SSG X Treatment of metastatic STS (VIG) 1991 – 97
SSG XII Metastasecetomy and CHT for lungmet – 97 from STS. An EORTC/SSG randomized phase III study
SSG XIII Treatment protocol for adults with – high-risk STS in extremities and trunk wall

8. High-risk STS (SSG XIII) doxorubicin/ifosfamide
Overall survival 5 4 3 2 1
1,0 ,9 ,8 ,7 ,6 ,5 ,4 ,3 ,2 ,1 3 -
year OS: 77%
Years
Promising preliminary results but:
Biased patient selection
Short follow-up time
Overall vs metastases-free survival

9. Adjuvant study for high-risk GIST
SSG XVIII
Adjuvant study for high-risk GIST R A N D O M I Z E
Imatinib Follow-up
12 months 48 months
36 months 24 months
Arm 1
Arm 2
Primary objective:
To investigate the recurrence-free survival in GIST patients with a high (>50%) risk of disease recurrence within the first 5 years following the diagnosis and treated with adjuvant imatinib mesylate either for 12 or 36 months.

10. Osteosarcoma SSG II Combination therapy in OS 1982 – 1990
SSG VIII Therapy of OS 1990 – 1998
ISG/SSG I An Italian-Scandinavian treatment and – 2000 research protocol for high-grade
osteosarcoma of the extremities
ISG/SSG II Treatment of metastatic and pelvic – 2003 osteosarcoma
SSG XIV A Scandinavian treatment research 2000 – 2004
protocol for extemity localized high-
grade osteosarcoma
Euroboss I A European treatment protocol for bone sarcoma in patients older than 40 years
Euramos I An American/European treatment protocol for OS in patients <40 years

11. European and American Osteosarcoma Study Group
Euramos-1
A randomised trial of the
European and American Osteosarcoma Study Group

12. EURAMOS 1 Euramos-1 Euramos-1
4 y anticipated accrual time (1400 pts). Covers a population >0.5 billion people
Objectives
Event-free survival
Overall survival
Short-term toxicity
Long-term toxicity
Quality-of-life
Euramos-1
Optimize the treatment of patients suffering from osteosarcoma.
Open for all patients with resectable high-grade osteosarcoma of the limbs or axial skeleton
The trial takes into account the strong prognostic value of tumor response to preoperative chemotherapy and divides patients accordingly

13. Ewing´s sarcoma SSG IV Combined modality therapy in EWS 1984 – 90
SSG IX Therapy of EWS 1990 – 99
ISG/SSG III ISG/SSG treatment protocol for non-metastatic EWS
ISG/SSG IV ISG/SSG treatment protocol for 1999
high-risk EWS

14. Translational Sarcoma Research
Future directions
Cancer Registries
Biobanks
Translational Sarcoma Research